Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Selling, General and Administrative Expenses

Last Annual Value

52.35M

3-Year CAGR

21%

5-Year CAGR

75%

10-Year CAGR

45%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Selling, General and Administrative Expenses

PRME · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
52.35M
6.5%30.3%N/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
51.78M
4.9%42.4%N/A
119.98M
33.4%20.9%31.2%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
29.16M
44.2%N/AN/A
51.70M
-0.1%-0.5%19.1%
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
18.37M
14.7%18.4%12.8%
171.47M
4.2%11.4%N/A
29.83M
19.6%39.5%N/A
92.07M
N/AN/AN/A
30.51M
48.7%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14